Interações de Linagliptina

Antidiabetic agents Hypoglycemia including fatal outcomes have been reported. (bula de Ciprofloxacino, Interações medicamentosas)

Hypoglycemia Chloroquine has been shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications (see PRECAUTIONS , Drug Interactions ). (bula de Cloroquina, Advertências)

Oral hypoglycemics Clinically significant hypoglycemia may be precipitated by the use of fluconazole with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined fluconazole and glyburide use. (bula de Fluconazol, Interações medicamentosas)

This warning is based on the study conducted by the University Group Diabetes Program (UGDP), a long-term prospective clinical trial designed to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with non-insulin-dependent diabetes. (bula de Glipizida + metformina, Contraindicações)

Hypoglycemia PLAQUENIL can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents [see Drug Interactions (7) ]. (bula de Hidroxicloroquina, Advertências e precauções)

Monitor blood glucose in patients with diabetes and assess if antidiabetic agent dose modifications are required. (bula de Abiraterona, Advertências e precauções)

Consideration should be taken in patients being treated with antidiabetic agents. (bula de Acetazolamida, Interações medicamentosas)

Oral Hypoglycemics Moderate doses of aspirin may increase the effectiveness of oral hypoglycemic drugs, leading to hypoglycemia. (bula de Ácido acetilsalicílico + dipiridamol, Interações medicamentosas)

Glyburide: In a trial of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose-lowering effect of glyburide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects. (bula de Acitretina, Interações medicamentosas)

Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA. (bula de Linagliptina, Advertências e precauções)

Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA. (bula de Linagliptina, Advertências e precauções)

Antidiabetic Agents: In rare cases, diabetic patients receiving an ACE inhibitor (including benazepril) concomitantly with insulin or oral antidiabetics may develop hypoglycemia. (bula de Anlodipino + benazepril, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (bula de Atazanavir, Advertências e precauções)

Antidiabetics: Increased risk of hypoglycemia ( 7.2 ) (bula de Benazepril, Interações medicamentosas)

Antidiabetic agents: Dosage adjustment of antidiabetic drug may be required. (bula de Benazepril + hidroclorotiazida, Interações medicamentosas)

Intervention Consider adding another antihyperglycemic agent in patients who require additional glycemic control. (bula de Bexagliflozina, Interações medicamentosas)

However, patients subject to spontaneous hypoglycemia, or diabetic patients receiving insulin or oral hypoglycemic agents, should be cautioned about these possibilities and bisoprolol fumarate should be used with caution. (bula de Bisoprolol, Advertências)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (bula de Bisoprolol + hidroclorotiazida, Precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (bula de Brimonidina + timolol, Advertências e precauções)

Oral antidiabetic agents and insulin, causing hypoglycemia by contributing an additive effect, if dosage of Butalbital, Aspirin, and Caffeine Capsules exceeds maximum recommended daily dosage. (bula de Butalbital + ácido acetilsalicílico + cafeína, Interações medicamentosas)

Evaluate the blood pressure and renal function of patients Examples: Metoprolol, propranolol Hypoglycemic Agents Clinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. (bula de Butalbital + ácido acetilsalicílico + cafeína + codeína, Interações medicamentosas)

Consider adding another antihyperglycemic agent in patients who require additional glycemic control [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3) ] . (bula de Canagliflozina, Interações medicamentosas)

Antidiabetic drugs (oral agents and insulin) − Dosage adjustment of the antidiabetic drug may be required. (bula de Candesartana + hidroclorotiazida, Interações medicamentosas)

Closely monitor for adverse reactions of CYP2C9 substrates where minimal concentration changes may lead to serious adverse reactions when used concomitantly with XELODA (e.g., anticoagulants, antidiabetic drugs). (bula de Capecitabina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Insulin and oral hypoglycemics action may be enhanced. (bula de Carvedilol, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Antidiabetics repaglinide, saxagliptin Antihelmintics and Antiprotozoals praziquantel Antimigraine Drugs ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine) eletriptan Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with ketoconazole tablets… (bula de Cetoconazol, Interações medicamentosas)

Oral Hypoglycemic Agents/Insulin: The concomitant use of clarithromycin tablets and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. (bula de Claritromicina, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Antidiabetic Drugs (Oral Agents and Insulin) - dosage adjustment of the antidiabetic drug may be required. (bula de Clorotiazida, Interações medicamentosas)

Caution should be exercised when used with antidiabetic drugs. (bula de Danazol, Interações medicamentosas)

…Coadministered Drug (Dose Regimen) * Dapagliflozin (Dose Regimen) * Effect on Dapagliflozin Exposure [% Change (90% CI)] C max AUC † No dosing adjustments required for the following: Oral Antidiabetic Agents Metformin (1000 mg) 20 mg ↔ ↔ Pioglitazone (45 mg) 50 mg ↔ ↔ Sitagliptin (100 mg) 20 mg ↔ ↔ Glimepiride (4 mg) 20 mg ↔ ↔ Voglibose (0.2 mg three times daily) 10… (bula de Dapagliflozina, Interações medicamentosas)

Initiation or dose adjustments of insulin or oral hypoglycemic agents may be required. (bula de Darunavir, Advertências e precauções)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (bula de Darunavir + cobicistate, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (bula de Dorzolamida + timolol, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. (bula de Enalapril + hidroclorotiazida, Precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Antidiabetic drugs (e.g., oral agents, insulin): Dosage adjustment of the antidiabetic drug may be required (see Precautions ). (bula de Espironolactona + hidroclorotiazida, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. (bula de Exenatida, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

• A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (bula de Fentermina, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (bula de Fludrocortisona, Interações medicamentosas)

As is true with many other types of medication when taken concurrently by patients with diabetes, insulin and/or oral hypoglycemic, dosage may need to be adjusted when therapy with PROZAC is instituted or discontinued. (bula de Fluoxetina, Advertências e precauções)

Some patients required either initiation or dose adjustments of insulin or oral hypoglycemic agents for treatment of these events. (bula de Fosamprenavir, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required (7.2) (bula de Hidroclorotiazida, Interações medicamentosas)

Antidiabetic Agents Clinical Impact: Corticosteroids in supraphysiologic doses may increase blood glucose concentrations. (bula de Hidrocortisona, Interações medicamentosas)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Irbesartana + hidroclorotiazida, Interações medicamentosas)

Antidiabetic Drugs Repaglinide Saxagliptin Monitor for adverse reactions. (bula de Itraconazol, Interações medicamentosas)

Hyperglycemia and Hypoglycemia : Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly. (bula de Lanreotida, Advertências e precauções)

Blood Glucose Disturbances Fluoroquinolones, including Levofloxacin in 5% Dextrose Injection, have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (bula de Levofloxacino, Advertências e precauções)

Worsening of Diabetic Control : May worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (bula de Levotiroxina, Advertências e precauções)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (bula de Levotiroxina + liotironina, Interações medicamentosas)

Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA. (bula de Linagliptina, Advertências e precauções)

• Hypoglycemia: Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents. (bula de Linezolida, Advertências e precauções)

• Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. (bula de Liotironina, Advertências e precauções)

Antidiabetics Concomitant administration of Zestril and antidiabetic medicines (insulins, oral hypoglycemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. (bula de Lisinopril, Interações medicamentosas)

Antidiabetic drugs (oral agents and insulin) - dosage adjustment of the antidiabetic drug may be required. (bula de Lisinopril + hidroclorotiazida, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Antidiabetic drugs: dosage adjustment of antidiabetic may be required. (bula de Losartana + hidroclorotiazida, Interações medicamentosas)

Antidiabetics : Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (bula de Metilprednisolona, Interações medicamentosas)

Insulin And Oral Antidiabetic Agents See Glucose Tolerance under PRECAUTIONS , General . (bula de Metolazona, Interações medicamentosas)

Antidiabetic drugs: Dosage adjustment may be required. (bula de Metoprolol + hidroclorotiazida, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Antidiabetic agents Carefully monitor blood glucose. (bula de Moxifloxacino, Interações medicamentosas)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (bula de Nadolol, Advertências)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Use of Antidiabetic Medications: Weight loss may cause hypoglycemia. (bula de Naltrexona + bupropiona, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Dipeptidyl peptidase 4 (DPP4) inhibitors saxagliptin ↑ saxagliptin Dosage adjustment of saxagliptin is recommended. (bula de Nirmatrelvir + ritonavir, Interações medicamentosas)

Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (bula de Octreotida, Advertências e precauções)

Fluoroquinolones have been associated with disturbances of blood glucose, including symptomatic hyperglycemia and hypoglycemia, usually in diabetic patients receiving concomitant treatment with an oral hypoglycemic agent (e.g., glyburide) or with insulin. (bula de Ofloxacino, Advertências)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (bula de Olmesartana + anlodipino + hidroclorotiazida, Interações medicamentosas)

• Antidiabetic drugs: Dosage adjustment may be required. (bula de Olmesartana + hidroclorotiazida, Interações medicamentosas)

A reduction in dose of oral hypoglycemic medication (e.g., sulfonylureas) or insulin may be required in some patients [see Clinical Studies (14) ] . (bula de Orlistate, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Beta-blockade also reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs. (bula de Pindolol, Advertências)

Congestive Heart Failure ACTOS, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when ACTOS is used in combination with insulin. (bula de Pioglitazona, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Congestive Heart Failure Pioglitazone, like other thiazolidinediones, can cause dose-related fluid retention when used alone or in combination with other antidiabetic medications and is most common when pioglitazone is used in combination with insulin. (bula de Pioglitazona + metformina, Advertências e precauções)

Antidiabetic Agents: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (bula de Prednisolona, Interações medicamentosas)

Antidiabetic agents: May increase blood glucose concentrations. (bula de Prednisona, Interações medicamentosas)

Monitor patients for the development of edema when co-administering LYRICA CR and thiazolidinedione antidiabetic agents. (bula de Pregabalina, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. (bula de Salsalato, Interações medicamentosas)

Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA. (bula de Linagliptina, Advertências e precauções)

Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA. (bula de Linagliptina, Advertências e precauções)

Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA. (bula de Linagliptina, Advertências e precauções)

Use caution in a patient with a history of angioedema to another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with TRADJENTA. (bula de Linagliptina, Advertências e precauções)

The doses of antidiabetic agents may require adjustment when HUMATROPE is initiated. (bula de Somatropina, Advertências e precauções)

Insulin and Oral Antidiabetics Hyperglycemia may occur, and the dosage of insulin or antidiabetic drugs may require adjustment. (bula de Sotalol, Interações medicamentosas)

Like other sulfonamide-containing drugs, sulfamethoxazole and trimethoprim potentiates the effect of oral hypoglycemics. (bula de Sulfametoxazol + trimetoprima, Interações medicamentosas)

• Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (bula de Sunitinibe, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

Antidiabetic drugs: Dosage adjustment may be required ( 7.6 ) (bula de Telmisartana + hidroclorotiazida, Interações medicamentosas)

This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. (bula de Tensirolimo, Advertências e precauções)

Masking of Hypoglycemic Symptoms in Patients with Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents. (bula de Timolol, Advertências e precauções)

Hypoglycemia: Consider lowering the dosage of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating TRADJENTA ( 5.2 ) (bula de Linagliptina, Advertências e precauções)

Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e.g., with rifampin). (bula de Linagliptina, Interações medicamentosas)

(See PRECAUTIONS . ) Antidiabetic Agents Concomitant use of ACE inhibitors and antidiabetic medicines (insulin or oral hypoglycemic agents) may cause an increased blood glucose lowering effect with greater risk of hypoglycemia. (bula de Trandolapril, Interações medicamentosas)

Hypoglycemia in Diabetic Patients Some MAOIs have contributed to hypoglycemic episodes in diabetic patients receiving insulin or other blood-glucose-lowering agents. (bula de Tranilcipromina, Advertências e precauções)

Antidiabetics: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. (bula de Triancinolona, Interações medicamentosas)

Dyrenium (triamterene) may raise blood glucose levels; for adult-onset diabetes, dosage adjustments of hypoglycemic agents may be necessary during and/or after therapy; concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (bula de Triantereno, Interações medicamentosas)

Oral Hypoglycemic Drugs Concurrent use with chlorpropamide may increase the risk of severe hyponatremia. (bula de Triantereno + hidroclorotiazida, Interações medicamentosas)

Hydrochlorothiazide: When administered concurrently, the following drugs may interact with thiazide diuretics: Antidiabetic Drugs (oral agents and insulin) - Dosage adjustment of the antidiabetic drug may be required. (bula de Valsartana + hidroclorotiazida, Interações medicamentosas)

Sulfonylurea Oral Hypoglycemics (CYP2C9 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Frequent monitoring of blood glucose and for signs and symptoms of hypoglycemia. (bula de Voriconazol, Interações medicamentosas)

Antidiabetic drug requirements (i.e., insulin) may be altered. (bula de Anfepramona (dietilpropiona), Interações medicamentosas)

Additional predisposing conditions include diabetes mellitus treated with oral hypoglycemic drugs or insulin, use of anorectic drugs, excessive use of alcohol, use of benzodiazepines, sedatives/hypnotics, or opiates. (bula de Bupropiona, Advertências e precauções)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (bula de Clozapina, Advertências e precauções)

Insulin and Oral Hypoglycemic Medications Requirements may be altered. (bula de Fendimetrazina, Interações medicamentosas)

Oral Hypoglycemic Agents In pharmacokinetic studies of lovastatin in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide (see CLINICAL PHARMACOLOGY , Clinical Studies in Adults ). (bula de Lovastatina, Interações medicamentosas)

Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out. (bula de Miconazol, Interações medicamentosas)

Moexipril hydrochloride has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H 2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. (bula de Moexipril, Interações medicamentosas)

Glucose Lowering Drugs Pioglitazone: Co-administration of pioglitazone for 7 days with 30 mg nifedipine ER administered orally q.d. for 4 days to male and female volunteers resulted in least square mean (90% CI) values for unchanged nifedipine of 0.83 (0.73-0.95) for C max and 0.88 (0.80-0.96) for AUC relative to nifedipine monotherapy. (bula de Nifedipino, Precauções)

Potentiation of the action of sulfonylurea hypoglycemic agents, thiazide diuretics and uricosuric agents may also be noted. (bula de Sulfadiazina, Interações medicamentosas)

Drug Interactions with Amlodipine In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual nitroglycerin, digoxin, warfarin, non-steroidal anti-inflammatory drugs, antibiotics, and oral hypoglycemic drugs. (bula de Telmisartana + anlodipino, Interações medicamentosas)

Hypoglycemic Agents: In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. (bula de Tolmetina, Interações medicamentosas)

In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of the suspect drug. (bula de Ziprasidona, Advertências e precauções)

Oral hypoglycemic agents Although sulindac and its sulfide metabolite are highly bound to protein, studies in which sulindac was given at a dose of 400 mg daily, have shown no clinically significant interaction with oral hypoglycemic agents. (bula de Sulindaco, Interações medicamentosas)